Search results
For ADHD core symptoms rated by clinicians in children and adolescents closest to 12 weeks, all included drugs were superior to placebo (eg, SMD –1·02, 95% CI –1·19 to –0·85 for amphetamines, –0·78, –0·93 to –0·62 for methylphenidate, –0·56, 0·66 to –0·45 for atomoxetine).
Oct 15, 2024 · The AAP guidelines for diagnosis and evaluation of ADHD recommend that healthcare providers complete these steps: Evaluate children and adolescents ages 4 to 18 years for ADHD if they are having academic or behavioral problems and show inattention, A hyperactivity, B or impulsivity.
Feb 1, 2022 · The recommended starting dose is 0.1 mg tablet at bedtime, which can then be increased to a twice-daily administration and subsequent careful uptitration. Doses higher than 0.4 mg/day are not recommended.
- Konstantin Mechler, Tobias Banaschewski, Sarah Hohmann, Alexander Häge
- 2021
Current clinical guidelines recommend an individualized multimodal treatment approach including psychoeducation, pharmacological interventions, and non-pharmacological interventions. Available medications include stimulants (methylphenidate, amphetamines) and non-stimulants (atomoxetine, guanfacine, clonidine).
- Konstantin Mechler, Tobias Banaschewski, Sarah Hohmann, Alexander Häge
- 2021
Jan 28, 2021 · For preschool-age children (ages 4 to <6), key action statement 5a recommends evidence-based parent training in behavior management. If parent training in behavior management is not available or is available and not effective, treatment with methylphenidate is recommended.
Mar 25, 2024 · We grouped evidence for medication, psychosocial interventions, parent support, nutrition and supplements, neurofeedback, neurostimulation, physical exercise, complementary medicine, school interventions, and provider approaches.
Jan 14, 2022 · Despite current recommendations, children/adolescents often receive relatively small daily dosages of stimulants in the community in the US––an average daily dose of ~20–25 mg of ...
